Maybody Majid, Madoff David C, Thornton Raymond H, Morales Steven A, Moskowitz Chaya S, Hsu Meier, Brody Lynn A, Brown Karen T, Covey Anne M
Memorial Sloan Kettering Cancer Center, Interventional Radiology Service, H1118, 1275 York Avenue, New York, NY 10065, USA.
Weill Cornell Medicine, Division of Interventional Radiology, 525 East 68th Street, P-518, New York, NY 10065, USA.
Clin Imaging. 2017 Mar-Apr;42:96-105. doi: 10.1016/j.clinimag.2016.11.018. Epub 2016 Nov 29.
To report 3 new cases of catheter-directed endovascular application of thrombin and explore trends by analysis of published case series.
Institutional Review Board approved this retrospective study. All cases of non-tumoral arterial embolization performed from January 2003 to January 2015 at our institution were retrospectively reviewed. Thrombin was used in 7 of 589 cases. In 3 cases intra arterial thrombin was injected via catheter to treat active hemorrhage. Four cases were excluded due to percutaneous injection into visceral pseudoaneurysms (n=3) and making ex vivo autologous clot to be injected via catheter (n=1). Fisher's exact and the Wilcoxon rank sum tests were used to assess for association with acute nontarget thrombosis.
Catheter-directed thrombin was used in 3/589 (0.5%) cases at our institution. All three cases were technically successful with no further bleeding (100%). Nontarget thrombosis of proximal branches occurred in 2 patients (67%) with no significant clinical consequences. Including our 3 cases, a total of 28 cases were reviewed. Of the variables examined-location (p=0.99), size (p=0.66) and etiology of vascular lesion (p=0.92), pseudoaneurysm neck anatomy (p=0.14), thrombin units (p=0.47), volume (p=0.76) or technique of use of small doses (p=0.99), use of other embolic material (p=0.67) and use of adjunct techniques (p=0.99)-none were found to be significantly associated with acute nontarget thrombosis. Technical success was 96% with no reports of reperfusion after treatment.
Catheter-directed endovascular thrombin can be an additional tool to treat pseudoaneurysms not amenable to conventional embolization. Further studies are required to optimize technique and outcomes.
报告3例经导管血管内应用凝血酶的新病例,并通过分析已发表的病例系列探讨相关趋势。
机构审查委员会批准了这项回顾性研究。对2003年1月至2015年1月在本机构进行的所有非肿瘤性动脉栓塞病例进行回顾性分析。589例病例中有7例使用了凝血酶。其中3例通过导管动脉内注射凝血酶治疗活动性出血。另外4例因经皮注射至内脏假性动脉瘤(3例)以及制作体外自体血凝块经导管注射(1例)而被排除。采用Fisher精确检验和Wilcoxon秩和检验评估与急性非靶血栓形成的相关性。
本机构在589例病例中有3例(0.5%)采用了经导管凝血酶治疗。所有3例技术上均获成功,无进一步出血(100%)。2例患者(67%)出现近端分支非靶血栓形成,但无明显临床后果。包括我们的3例病例在内,共回顾了28例病例。在所检查的变量中——血管病变的位置(p = 0.99)、大小(p = 0.66)和病因(p = 0.92)、假性动脉瘤颈部解剖结构(p = 0.14)、凝血酶单位(p = 0.47)、体积(p = 0.76)或小剂量使用技术(p = 0.99)、其他栓塞材料的使用(p = 0.67)以及辅助技术的使用(p = 0.99)——均未发现与急性非靶血栓形成有显著相关性。技术成功率为96%,治疗后无再灌注报告。
经导管血管内凝血酶可作为治疗不宜采用传统栓塞治疗假性动脉瘤的一种补充手段。需要进一步研究以优化技术和治疗效果。